BMY News and Press, Bristol-Myers Squibb Company From 05/11/24

2024-05-11 06:58:33 ET Summary Organon, Pfizer, and Bristol Myers all offer yields above 5% and can  compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff h...

2024-05-10 17:13:16 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: A Lost Decade? Bristol Myers Squibb: Tough Times Continue Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript FDA accepts Bristol Myers application for injected ...

Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated Opdivo ® (nivolumab) with ...

2024-05-10 14:13:46 ET More on Alphabet, Recursion, etc. Recursion Pharmaceuticals, Inc. (RXRX) Q1 2024 Earnings Call Transcript Bronte Capital - Alphabet: Could Not Find Anything We Liked More Google: The Recent Surge Is Far From Over CrowdStrike, Google exp...

2024-05-10 09:45:00 ET It's easy to find stocks that are lagging broader equities, even in a bull market like the one we're currently in. It's harder to find beaten-down stocks that still look worth buying and holding onto for a while. Some corporations are condemned to deliver subpar finan...

2024-05-09 11:10:00 ET Summary April was a reset month for US equity markets, as investors digested persistent inflation data and declining GDP growth. The Morningstar Wide Moat Focus Index modestly lagged the S&P 500 Index in April, losing 4.96%. The Morningstar US Small-...

2024-05-07 20:26:14 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-05-06 12:11:46 ET More on Bristol-Myers Squibb Company Bristol-Myers Squibb: A Lost Decade? Bristol Myers Squibb: Tough Times Continue Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Pharma R&D productivity seen improving for the ...

Application based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of nivolumab to evaluate and demonstrate noninferior pharmacokinetics, efficacy and consistent safety vs. its intravenous formulation Subcutaneous nivolumab has potential to be th...

Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared to investigator’s choice of chemotherapy European Medicin...